[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nicole Stoffel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100623310","absorption-of-iron-from-stabilized-lactoferrin-a-study-in-women-with-iron-deficiency-100623310",false,"NCT07394972","Absorption of Iron From Stabilized Lactoferrin: A Study in Women With Iron Deficiency","Iron Absorption From Stabilized Lactoferrin: An Experimental Study in Iron Deficient Women (LOBSTER)","LOBSTER","Inclusion Criteria:\n\n* Serum ferritin \\\u003C 45 µg\u002FL (iron depleted)\n* Body weight \\\u003C 70 kg\n* Body mass index 18,5 - 24,9 kg\u002Fm2 (normal weight)\n* Hemoglobin (Hb) \\> 120 g\u002FL (nonanemic)\n* C-reactive protein (CRP) \\\u003C 5 mg\u002FL (no inflammation)\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Strictly vegan\n* Cigarette smoking (\\> 1 cigarette \u002F week)\n* Gastrointestinal or metabolic disorders affecting iron absorption or metabolism\n* Use of medication known to affect iron metabolism (oral contraceptives are allowed)\n* Intake of vitamin and mineral supplements in the 2 weeks before study start and during the study\n* Blood transfusion, blood donation, or significant blood loss during the previous 4 months\n* once enrolled, inability to follow study procedures or major illness\n* Participation in another study with investigational drug within the 30 days preceding and during the present study",true,"FEMALE","18 Years","45 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"NA","Lactoferrin (LF) is a natural iron-binding protein found in milk. It exists either in an iron-free state (apo-LF) or bound to iron (holo-LF). Whether LF binds iron to facilitate its absorption and\u002For to sequester iron from potential enteropathogens remains uncertain. However, while LF is a promising tool for treating iron deficiency, it is sensitive to heat during food processing and to the acidic environment of the human stomach. This degradation often causes LF to lose its functional properties before it can promote iron absorption effectively.\n\nThis study aims to evaluate whether encapsulating apo-LF (either alone or in combination with iron) can protect LF from digestion and enhance iron absorption. Using a randomized, crossover design, different encapsulation methods will be compared to determine which results in the highest iron absorption in women with iron deficiency.\n\nAll test compounds will be labeled with stable iron isotopes. Participants will consume the labeled compounds with a test meal or water in a randomized order, allowing for within subject comparisons. Fractional iron absorption will be measured 17 days after administration via the incorporation of labeled iron into red blood cells.",[29],"Iron Deficiency (Without Anemia)",[31,32,33,34,35,36,37],"Lactoferrin","Iron Deficiency","Iron Absorption","Iron Fortification","Stable Iron Isotopes","Dietary Supplements","Iron Bioavailability","RECRUITING","2026-02-11",{"date":41,"type":42},"2026-02-12","ACTUAL",{"date":44,"type":23},"2026-02-17",{"date":46,"type":23},"2026-05",{"name":48,"class":49},"Nicole Stoffel","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100578840","the-effects-of-iron-treatment-on-malaria-and-measles-vaccine-response-in-kenyan-infants-with-iron-deficiency-100578840","NCT06816524","The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency","Inclusion Criteria:\n\n* Subject's caregiver is willing and able to give informed consent\n* Male or Female, 6 months (+\u002F- 2 weeks) of age\n* Mother at least ≥15 years of age\n* Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) \\>61 μmol\u002Fmol heme)\n* With or without anemia (anemia defined by Hb \\\u003C110 g\u002FL)\n\nExclusion Criteria:\n\n* Severely anemic (Hb \\\u003C70 g\u002FL)\n* Malaria vaccination prior to enrollment\n* Medical condition that precludes study involvement\n* Iron supplementation 2 weeks before enrollment\n* Acute or chronic infection (e.g. HIV)\n* Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).","ALL","6 Months",{"count":60,"type":23},324,[26],"Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.\n\nIn this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21\u002FMatrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.",[64],"Iron Deficiencies",[66,67,68,69],"Iron deficiency","Vaccine immunogenicity","Malaria","Measles","NOT_YET_RECRUITING","2025-12-19",{"date":73,"type":42},"2025-12-26",{"date":75,"type":23},"2026-01-05",{"date":77,"type":23},"2028-04-30",{"name":48,"class":49},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":50},"100617181","the-effect-of-oral-iron-supplements-on-insulin-and-glucose-metabolism-in-overweight-and-obese-women-100617181","NCT07315282","The Effect of Oral Iron Supplements on Insulin and Glucose Metabolism in Overweight and Obese Women","Inclusion Criteria:\n\n* BMI ≥ 27.5 kg\u002Fm2\n* serum ferritin \\\u003C30 μg\u002FL\n* hemoglobin ≥ 11 g\u002Fdl\n* fasting blood glucose \\\u003C 5.6 mmol\u002FL\n\nExclusion Criteria:\n\n* intravenous or high dose oral iron in the preceding 2 months\n* medical disorders are known to affect iron absorption or metabolism, or T2DM\n* cigarette smoking\n* recent blood transfusion or major blood loss",{"count":86,"type":23},70,[26],"The study will be a randomized, double-blind, 17-day metabolic intervention trial including 14 days of high-dose or low-dose iron supplementation. A total of 70 overweight or obese (OW\u002FOB) women will be enrolled. Participants will be individually randomized into either the high-iron or low-iron group.\n\nWomen in the low-iron group will receive 15 mg of iron as ferrous fumarate daily for 14 days, while women in the high-iron group will receive 195 mg of iron as ferrous sulfate daily for 14 days.\n\nThe study consists of three visits in total. On Day 0, a fasting blood sample will be collected and an OGTT will be performed, with additional blood samples collected at 1 hour and 2 hours post-OGTT. The OGTT will be repeated on Day 14, after 14 days of oral iron supplementation, and again on Day 17, four days after oral iron supplementation has been stopped",[90],"Overweight and Obese Women","2025-12-18",{"date":93,"type":42},"2026-01-02",{"date":95,"type":23},"2025-12-23",{"date":97,"type":23},"2026-06-30",{"name":48,"class":49},""]